Gastroenterology Market Size, Share and Trends 2025 to 2034

Revenue, 2025

USD 38.80 Bn

Forecast Year, 2035

USD 69.48 Bn

CAGR, 2026 - 2035

6%

Report Coverage

Global

What is Gastroenterology Market Size?

The global gastroenterology market size is expected to be valued at USD 41.13 billion in 2025 and is anticipated to reach around USD 69.48 billion by 2034, expanding at a CAGR of 6% over the forecast period from 2025 to 2034. The gastrointestinal market is driven by the minimal invasive gastrointestinal diagnostics and the requirement for superior gastrointestinal therapeutics.

Market Highlights

• By region, North America dominated the gastroenterology market in 2025.
• By region, the Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• By type, the branded segment dominated the market in 2025.
• By type, the generics segment is expected to grow at the fastest CAGR during the forecast period.
• By distribution channel, the retail pharmacies segment dominated the market in 2025.
• By distribution channel, the online pharmacies segment is expected to grow at the fastest CAGR during the forecast period.
• By application, the Crohn's disease segment dominated the market in 2025.
• By application, the ulcerative colitis segment is expected to grow at the fastest CAGR during the forecast period.
• By route of administration, the injectables segment dominated the gastroenterology market in 2025.
• By route of administration, the oral segment is expected to grow at the fastest CAGR during the forecast period.

What is gastroenterology?

Gastrointestinal disorders are gastrointestinal illnesses that affect the colon, small and large intestines, and the rectum. Irritable bowel syndrome, peptic ulcer diseases, and constipation make up most of the problems. These are all characterized by symptoms like discomfort, bloating, diarrhea, nausea, and vomiting. The term "gastrointestinal therapies" refers to a class of medications that includes the following: Prilosec, Aciphex, Afinitor, Akynzeo, and Akynzeo.

The primary reasons propelling market expansion include expanding geriatric population, geriatric occurrences, overcrowding in the hospital outpatient department (HOPD), and rising demand for ambulatory treatments to minimize irrational hospitalization costs.

The market will grow in size during the projected period as a result of factors such as an increase in chronic diseases, a growth in the older population, unhealthy lifestyles, and an increase in the number of surgeries in the world.

Key AI Integration in the Gastroenterology Market

AI is transforming the gastroenterology sector, impacting correct diagnosis, procedure effectiveness, and quick clinical study. The automated image recognition algorithms participate in endoscopy and colonoscopy procedures with an increasing level of accuracy and speed in diagnosis. Machine learning algorithms can also help in predicting disease, planning treatment, and stratifying patients, ensuring tailored care.

Gastroenterology Market Growth Factors

The rising incidence of gastrointestinal disorders brought on by unhealthful eating patterns, the expansion of clinical studies with reliable findings, rising healthcare costs, and the rise in the elderly population are the main drivers of the gastroenterology market. But it's anticipated that the market will not grow as quickly as it may due to drug side effects and strict regulatory rules for drug approval.

In the near future, the gastroenterology industry will experience significant demand due to rising demand for self-medication and regenerative medicines, as well as several patient support programs implemented in emerging nations. Hospital patient loads have increased as a result of an increase in surgical operations, particularly small inpatient surgeries such as minor joint repair, abdominal hernia repair, gall bladder removal, cataract surgery, and other treatments. One of the main forces fueling the market's expansion is the increasing number of patients.

Market Outlook

• Industry Growth Overview: The gastroenterology market is growing, driven by the rising prevalence of digestive diseases, an increasing demand for well-developed endoscopic and minimally invasive treatments, and an intensifying worldwide geriatric population. The advancement of novel diagnostic devices and therapeutic interventions drives the growth of the market.
• Global Expansion: Market growth is expanding due to the rising prevalence of gastrointestinal disorders, technological development such as AI-driven and capsule endoscopy, and amplified demand for minimally invasive measures. North America is dominant in the market due to high medical care spending and growing medical infrastructure.
• Major investors: Large pharmaceutical and healthcare tools organizations also have various private equity (PE) firms. This includes AbbVie Inc., Johnson & Johnson, Abbott Laboratories, Boston Scientific Corporation, and Takeda Pharmaceutical Company

Gastroenterology Market Trends

• Growing Adoption of AI-Powered Diagnostics: With the increasing sophistication of robots in visualizing the endoscopy field, these algorithms are increasingly used in the field of medicine, such as the potential to improve diagnosis and to detect gastrointestinal disease.
• Rising Demand for Minimally Invasive Procedures: Increased demand for procedures with lower tissue disruption and quicker recovery from the procedure due to less pain/less and more comfort for the patient/providers, etc.
• Increasing Prevalence of Gastrointestinal Disorders: The gastrointestinal disorders, like colorectal cancer, inflammatory bowel disease, gastroesophageal reflux, and irritable bowel syndrome, are growing in prevalence, with a need for advanced solutions in the gastroenterology diagnosis and treatment area.
• Expansion of Advanced Endoscopy Technologies: By the adoption of high definition and capsule, robot-assisted endoscopy techniques, with more visual, more accurate diagnosis, and more effective therapy, it can add more disease population detection and treatment in the initial stage.

Market Scope

Market Dynamics

Drivers

The growing size and quantity of investments made in the healthcare system by governments and commercial companies of different countries are one of the primary drivers fueling the market's growth. The rapid economic development and the rising expense of healthcare would give more developing nations better access to high-quality care. Governments from several countries are attempting to improve residents' access to high-quality medical care and increase payment choices.

Additionally, pharmaceutical and biotechnology businesses are focusing more on R&D to find and create new medications for treating gastrointestinal illnesses, expanding their product pipeline. Additionally, the global increase in drug development for gastrointestinal illnesses is anticipated to contribute to the growth.

Restraints

The market's expansion is constrained by the increase in healthcare costs. In addition, the market's expansion is constrained by the lack of access to medical services and treatments. Among inflammatory diseases, chronic gastritis is quite frequent. In many patients, the inflammatory stomach mucosa exhibits a tendency to atrophize over time (atrophic gastritis). Gastritis typically lasts a lifetime, and patients with autoimmune chronic corpus gastritis have very low chances of spontaneous recovery.

The Helicobacter pylori bacterium has been linked to gastritis. Gastric secretory processes, such as pepsin, gastric acid secretion, and gastrin, are hampered by inflammation and atrophy of the gastric mucosa. Therefore, it is anticipated that the gastroenterology field will suffer from the lack of effective and long-lasting treatments for gastrointestinal diseases.

Market Opportunities

The market will rise in the future as technologically sophisticated surgical techniques like minimally invasive operations become more commonplace, and as patients come to accept and become more aware of these procedures being provided in ambulatory facilities. This represents a significant prospective growth opportunity for the market during the anticipated term.

Segment Insights

Type Insights

The Branded Segment Held the Largest Share of the Gastroenterology Market in 2025

The branded segment held a dominant position in the gastroenterology market in 2025 due to a strong demand for advanced biologic therapies. Branded drugs have their proven efficacy and safety profile in chronic gastrointestinal diseases. Prescribing brand names is more usual since the clinical trial results and experience with the product are already established.

The generics segment is expected to witness strong growth during the forecast period as affordable treatment options are becoming popular. Major gastroenterology drugs are soon to be used with generic drugs as they are subject to patent expiration. With the increasing acceptance of methods to treat cost-effectiveness, healthcare providers are making use of them to reduce the overall expenditure of therapy.

Distribution Channel Insights

The Retail Pharmacies Segment Dominated the Gastroenterology Market in 2025

The retail pharmacies segment dominated the gastroenterology market in 2025 as they were easily available across urban and rural areas. It is very common in retail pharmacies for healthcare professionals to confide in patients their medications for gastrointestinal use. Expand the range of products and allow access to pharmacists for advice on product use to increase ease of use and progress support.

The online pharmacy segment is expected to grow significantly during the forecast period due to the adoption of digital healthcare services. Convenient medication orderers with home delivery services are wanted by consumers. The trend in telemedicine service utilization and prescription filling is helping prescription use through online services.

The hospital pharmacies segment is projected to grow at a notable pace as the demand in hospitals to use specialty gastrointestinal drugs will play a crucial role. Hospital pharmacists' services are critical in the management of serious and complicated gastrointestinal diseases. The growth of hospitals stimulates demand as a result of biological treatment and injectable treatment provided by the administrator.

Application Insights

The Crohn's Disease Segment Dominated the Gastroenterology Market in 2025

The Crohn's disease segment dominated the market in 2025, driven by increasing prevalence and regular requirement for treatment in the long-term for Crohn's disease. Requires the use of disease management and often biologics or immunomodulators for much of the treatment. Better diagnostic technologies have helped to detect more cases and make treatment more effective.

The ulcerative colitis segment is expected to grow steadily during the forecast period, owing to increasing awareness and diagnosis of the condition. Treatment for more advanced disease states, defined by new biologics/ target drugs, leads to better management and clinical goals. Investing in research increases treatment alternatives for those who have been impacted.

The GERD segment is projected to grow at a healthy pace as a result of the increase in unhealthy lifestyles and obesity patterns. Acid reflux is a growing disease, and more and more individuals are turning to treatment for it. As awareness grows, more people will be alerted to it, diagnosis will begin at a younger age, and timely action will be taken regularly.

The IBS segment is expected to experience considerable growth durin0g the forecast period, driven by the growing occurrence of digestive disorders. Contributing factors to its spread are lifestyle changes, obesity, and stress. The progress in the field of microbiome has led to exciting new treatment possibilities.

Route of Administration

The Injectable Segment Dominated the Gastroenterology Market in 2025

The injectable segment dominated the gastroenterology market in 2025. Patients with gastrointestinal (GI) conditions were treated using widespread biologic use. Medicines given by injection bring rapid-acting results and improved control of the disease. Healthcare providers also prefer a treatment method for moderate-to-severe inflammatory bowel diseases, such as injectables.

The oral segment is expected to witness notable growth driven by greater patient convenience and ease of use. Tablet medications are frequently used to treat GERD, IBS, and ulcers. The invention of pills and tablets has improved, with the help of which drugs are being made more efficient and more patient-friendly.

Regional Insights

North America will lead the Global Gastroenterology Market in 2025

North America dominated the global gastroenterology market in 2025 due to the advanced health system infrastructure and high healthcare expenditure. There is a wealth of patients in the area suffering from digestive diseases such as inflammatory bowel disease, gastroesophageal reflux, colorectal cancer, and others. The presence of the leading pharmaceutical companies, the favorable reimbursement policies, and the increased utilization of biologics are also supporting the growth of the market.

U.S. Market Trends

The U.S. represents a large market for gastroenterology due to the high prevalence of gastrointestinal conditions and high health care expenditure. The market is expanding at a steady rate with the increased use of cutting-edge biologics, targeted treatment modalities, and less invasive diagnostics. The nation also has ample investments in clinical research, diagnostics with AI, and precision medicine.

U.S. Gastroenterology Market Size and Growth 2025 to 2034

The U.S. gastroenterology market size is exhibited at USD 10,94 billion in 2025 and is projected to be worth around USD 18.86 billion by 2034, growing at a CAGR of 6.21% from 2025 to 2034.

Technological advancements, an increase in gastrointestinal diseases, an increase in the number of geriatric and obese people, and an increase in research and development activities with the presence of major market players are some of the factors propelling market growth in the North American region.

Patients with co-morbid diseases, those who have impaired immune systems, and those who are malnourished and immunosuppressed have been shown to experience more severe COVID-19 infections. Crohn's disease and ulcerative colitis are both intestinal and extraintestinal manifestations of the chronic remitting and relapsing condition known as inflammatory bowel disease (IBD). Due to their frequent malnutrition and use of immunosuppressive drugs, people with inflammatory bowel disease (IBD) may be significantly more likely to get COVID-19 infection.

Asia Pacific is Undergoing the Fastest Growth in the Gastroenterology Market

Asia Pacific is expected to grow at the fastest rate in the gastroenterology market, as the growing burden of digestive diseases and rising investments in healthcare, as well as a wider range of healthcare access. The increasing urbanization, shifting food consumption patterns, and a growing elderly population are responsible for the increased prevalence of gastrointestinal disease in the region. The Government of India is giving much importance to health awareness programmes and health infrastructure.

China Market Trends

China's gastroenterology market is anticipated to grow significantly, driven by the surge in digestive disorders and rapidly growing infrastructure in the healthcare sector. The gastrointestinal disease space has advanced, driving the growth of both advanced therapeutics and diagnostics, and healthcare costs. From government policies, the expansion of access to and awareness about healthcare services is favored, and this is supporting market growth.

Advancements in the Gastroenterology Market in Europe

Europe is expected to witness significant market growth throughout the forecast period, driven by the increasing incidence of gastrointestinal diseases and high market penetration of new treatment technologies. The region is well established in terms of health care systems, health care reimbursement, and research. The replacement of biological therapy with biosimilars and bio-personalisation is changing the treatment landscape.

Germany Market Trends

Germany represents a major market for gastroenterology owing to the significant financial allocation towards health care and advanced health care infrastructure. The country sees early diagnosis and treatment of gastrointestinal disorders as a priority, and modern diagnostic technologies are widely developed. The growth of therapeutic alternatives is expected to be supported by the increasing incidence of inflammatory bowel disease, colorectal cancer, and GERD in the future.

Key Trends in the Gastroenterology Market in Latin America

Latin America is expected to witness significant growth in the gastroenterology market owing to the rise in awareness of the healthcare sector and enhanced access to healthcare services. Treatment solution demand is growing as the population in urban areas increases, diets change, and gastrointestinal issues arise. Healthcare infrastructure & disease management programs are being invested in by governments and private healthcare providers.

Brazil Market Trends

Brazil represents a significant market for gastroenterology with an ever-growing diagnostic and treatment burden of gastrointestinal diseases and conditions. The advanced the treatment and sophisticated need for advanced treatment has increased due to greater expenditure to provide health care services and greater accessibility. More knowledge about the gastrointestinal diseases and preventive care is leading to a better time of diagnosis and intervention.

Growth of the Middle East and Africa in the Gastroenterology Market

The Middle East and Africa region is expected to witness significant growth in the gastroenterology market, driven by rising investments in the healthcare sector and improvement in the availability of specialized gastroenterology medical services. With the rise in attention to gut health and gastrointestinal disorders, the mushroom market is booming. The governments of the region are funding projects to modernize health facilities and handle diseases.

Saudi Arabia Market Trends

Saudi Arabia represents a significant market for gastroenterology, with its increasingly robust healthcare industry. The growing occurrence of digestive disorders, obesity, and lifestyle-related diseases has led to a rise in the demand for gastroenterology treatment. The government is helping to make better use of specialist services and cutting-edge treatments within the programmes of change in health care.

Gastroenterology Market- Value Chain Analysis

• R&D: Gastroenterology R&D involves many processes of preclinical research, discovery, clinical trials, and government approval to grow new diagnostics, therapeutic drugs, and less invasive procedures.
  Key Players: American Gastroenterological Association
• Clinical Trials: It involves four main phases such as phase 1 (safety and dosage), phase 2 (effectiveness and side effects), phase 3 (confirming efficacy and comparison), and phase 4 (post-marketing surveillance)
  Key Players: GI Alliance and Gastro Health
• Patient Services: This service includes diagnostic and therapeutic endoscopy, such as colonoscopy, upper endoscopy, and ERCP, imaging tests, such as CT, MRI, and EUS, laboratory tests, such as blood and stool, and surgical procedures for a range of digestive disorders.

Competitive Landscape

The gastroenterology market is moderately consolidated as the major players in the market are AbbVie Inc., Johnson & Johnson, Pfizer Inc., Sanofi, and F. Hoffmann-La Roche Ltd. These companies are all engaged in the business of biologics, targeted therapies, and state-of-the-art diagnostics to strengthen their market presence. They continue to invest in research and development, acquisitions, and new product launches to strengthen their gastroenterology business areas.

Strategic links among healthcare service providers, biotechnology, and pharmaceutical firms are rapidly improving the innovation process. Companies are also trying to get approval and commercialisation of new treatments, reflecting greater access to the treatment.

Key Players in Gastroenterology Market and Their Offerings

Recent Development

• In July 2025, Bausch Health Companies Inc. and its gastroenterology unit, Salix Pharmaceuticals, rolled out its first direct-to-consumer “I Wish I Knew” marketing campaign for Xifaxan (rifaximin). The campaign is designed to help inform healthcare providers (HCPs) and patients of the risk of recurrence for those with overt hepatic encephalopathy (OHE) and to educate patients about the only Food and Drug Administration (FDA) approved drug indicated to reduce the risk of OHE recurrence in an adult. (Source: https://ir.bauschhealth.com)

Segments Covered in the Report

By Type

• Branded
• Generics

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Application

• Crohn's Disease
• Ulcerative Colitis
• GERD
• IBS
• Others

By Route of Administration

• Injectable
• Oral & Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa